BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (9/28/2023, 7:00:00 PM)
After market: 89.25 0 (0%)89.25
-1.12 (-1.24%)
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,082 full-time employees. The firm's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company’s clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.
Company Info
BIOMARIN PHARMACEUTICAL INC
105 Digital Dr
Novato CALIFORNIA 94901
P: 14155066700.0
CEO: Jean-Jacques Bienaime
Employees: 3082
Website: https://www.biomarin.com/
BMRN News
6 days ago - The Motley Fool4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market DipA nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.
8 days ago - BioMarin Pharmaceutical Inc.BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
14 days ago - Market News VideoFirst Week of November 17th Options Trading For BioMarin Pharmaceutical (BMRN)14 days ago - BioMarin Pharmaceutical Inc.BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
14 days ago - Investor's Business DailyHave Million-Dollar Gene Therapies Finally Reached An Inflection Point?Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
18 days ago - BioMarin Pharmaceutical Inc.BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will...
BMRN Twits
Here you can normally see the latest stock twits on BMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
